Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Up 6.3%

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSGet Free Report)’s share price shot up 6.3% on Friday . The company traded as high as $27.02 and last traded at $26.76. 133,079 shares were traded during mid-day trading, a decline of 80% from the average session volume of 680,781 shares. The stock had previously closed at $25.17.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TARS. Barclays raised their price target on shares of Tarsus Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, May 10th. Jefferies Financial Group raised their price target on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. HC Wainwright raised their price target on shares of Tarsus Pharmaceuticals from $57.00 to $61.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Finally, Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $59.00 to $61.00 and gave the company an “outperform” rating in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $50.38.

Read Our Latest Stock Analysis on Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Price Performance

The company has a quick ratio of 7.92, a current ratio of 8.01 and a debt-to-equity ratio of 0.11. The stock’s fifty day simple moving average is $33.05 and its 200 day simple moving average is $30.35.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.14. The business had revenue of $27.61 million during the quarter, compared to analyst estimates of $17.94 million. On average, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.75 earnings per share for the current year.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Swiss National Bank increased its holdings in shares of Tarsus Pharmaceuticals by 1.4% during the 1st quarter. Swiss National Bank now owns 42,433 shares of the company’s stock worth $1,542,000 after buying an additional 600 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Tarsus Pharmaceuticals by 22.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,560 shares of the company’s stock valued at $92,000 after purchasing an additional 824 shares during the last quarter. Callan Capital LLC increased its holdings in Tarsus Pharmaceuticals by 11.5% in the 4th quarter. Callan Capital LLC now owns 16,950 shares of the company’s stock valued at $343,000 after purchasing an additional 1,750 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in Tarsus Pharmaceuticals by 11.5% in the 4th quarter. Janney Montgomery Scott LLC now owns 24,227 shares of the company’s stock valued at $491,000 after purchasing an additional 2,500 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Tarsus Pharmaceuticals by 71.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,567 shares of the company’s stock valued at $239,000 after purchasing an additional 2,735 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

(Get Free Report)

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Featured Stories

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.